Ulcerative Colitis

Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting.

In RA (3 mg/kg), CD (5 mg/kg), PsA (5 mg/kg), and UC (5 mg/kg), REMICADE is a two-hour infusion administered every 8 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6.

As a result, REMICADE patients may require as few as six treatments each year.

In AS (5 mg/kg), REMICADE is a two-hour infusion administered every 6 to 8 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6.

Centocor discovered REMICADE and has exclusive marketing rights to the product in the United States.

Schering-Plough markets REMICADE in all countries outside of the United States, except in Japan and parts of the Far East where Tanabe Seiyaku, Ltd.

markets the product and in China where Xian- Janssen markets REMICADE.

Important Safety Information Many people with heart failure should not take REMICADE; so prior to treatment you should discuss any heart condition with your doctor.

Tell your doctor right away if you develop new or worsening symptoms of hea...

Read more...